Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imukin for the prevention of hospital-acquired pneumonia
NCT04793568Phase 2Unknown
- Sponsor
- CHU de Nantes
- Start
- Mar 2021
- Primary completion
- Nov 2021
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of interferon gamma-1b in hospital-acquired pneumonia (HAP), sponsored by CHU de Nantes. Primary endpoint: Prevention of hospital-acquired pneumonia at 28 days. Status: unknown.
02
Drugs
interferon gamma-1b
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT04793568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793568.